Novo Nordisk Inc. recently commissioned Milliman to analyze the impact of modifying Part D policy to permit anti-obesity medications (AOMs) approved by the Food and Drug Administration to be covered under Medicare Part D. In the past several years, there have been substantial changes in the perception of obesity treatments and advances in AOMs, specifically glucagon-like peptide-1 agonists. This report focuses on how requiring Part D coverage of the AOM class could affect Medicare stakeholder costs. The report discusses: 

• The AOM landscape and recent market events
• AOM coverage in Part D
• Stakeholder impacts for government and member costs

This report was commissioned by Novo Nordisk.